BRPI1011453A2 - formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina - Google Patents

formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina

Info

Publication number
BRPI1011453A2
BRPI1011453A2 BRPI1011453A BRPI1011453A BRPI1011453A2 BR PI1011453 A2 BRPI1011453 A2 BR PI1011453A2 BR PI1011453 A BRPI1011453 A BR PI1011453A BR PI1011453 A BRPI1011453 A BR PI1011453A BR PI1011453 A2 BRPI1011453 A2 BR PI1011453A2
Authority
BR
Brazil
Prior art keywords
formulation
drug
dosage form
asenapine hemipamoate
hemipamoate salt
Prior art date
Application number
BRPI1011453A
Other languages
English (en)
Inventor
Gerardus Johannes Kemperman
Johannes Antonius Hendrikus Van Laarjoven
Werenfridus Adrianus Faassen
Original Assignee
Msd Oss Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Oss Bv filed Critical Msd Oss Bv
Publication of BRPI1011453A2 publication Critical patent/BRPI1011453A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI1011453A 2009-06-24 2010-06-24 formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina BRPI1011453A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22002709P 2009-06-24 2009-06-24
PCT/EP2010/058960 WO2010149727A2 (en) 2009-06-24 2010-06-24 Injectable formulations containing asenapine and method of treatment using same

Publications (1)

Publication Number Publication Date
BRPI1011453A2 true BRPI1011453A2 (pt) 2016-03-15

Family

ID=43386952

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011453A BRPI1011453A2 (pt) 2009-06-24 2010-06-24 formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina

Country Status (13)

Country Link
US (2) US8658687B2 (pt)
EP (1) EP2453870A2 (pt)
JP (1) JP5801295B2 (pt)
KR (1) KR101435296B1 (pt)
CN (1) CN102596172A (pt)
AR (1) AR077225A1 (pt)
AU (1) AU2010264670A1 (pt)
BR (1) BRPI1011453A2 (pt)
CA (1) CA2766291C (pt)
MX (1) MX2012000061A (pt)
RU (1) RU2012102247A (pt)
TW (1) TW201113018A (pt)
WO (1) WO2010149727A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524920A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Asenapine Hydrochloride Salt Forms
EP2524921A1 (en) * 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Salts of Asenapine
TWI552751B (zh) * 2011-06-20 2016-10-11 H 朗德貝克公司 投予4-((1r,3s)-6-氯-3-苯基-二氫茚-1-基)-1,2,2-三甲基-哌及其鹽用於治療精神分裂症的方法
CN104507472B (zh) * 2012-07-26 2016-10-05 久光制药株式会社 贴附剂
JP6360488B2 (ja) * 2012-11-01 2018-07-18 トレント・ファーマシューティカルズ・リミテッドTorrent Pharmaceuticals Limited 非経口投与のためのタペンタドールの薬学的組成物
FR3020810B1 (fr) * 2014-05-06 2016-05-06 Servier Lab Nouveau sel de l'ivabradine et son procede de preparation.
WO2016198113A1 (en) 2015-06-11 2016-12-15 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
ES3001152T3 (es) 2016-12-20 2025-03-04 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polisiloxano o poliisobutileno
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
SI3565528T1 (sl) * 2017-01-09 2025-10-30 Relmada Therapeutics, Inc. Injekcijske suspenzije
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
AU2018363686B2 (en) * 2017-11-07 2023-11-23 Intervet International B.V. Process for preparing large size isoxazoline particles
PE20201150A1 (es) * 2017-11-07 2020-10-26 Intervet Int Bv Composiciones farmaceuticas inyectables de isoxazolina y usos de las mismas
EP3810099A1 (en) 2018-06-20 2021-04-28 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN116139080B (zh) * 2020-08-26 2025-07-29 上海云晟研新生物科技有限公司 卡利拉嗪药物组合物、制备方法及应用
CN120698949A (zh) * 2022-02-22 2025-09-26 上海云晟研新生物科技有限公司 卡利拉嗪药用盐及其晶型、药物组合物、制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
EP0569096A1 (en) * 1992-05-08 1993-11-10 Akzo Nobel N.V. Depot preparation
CA2095499A1 (en) * 1992-05-08 1993-11-09 Petrus J. M. Van Den Oetelaar Depot preparation
CN1079670C (zh) 1994-03-02 2002-02-27 阿克佐诺贝尔公司 舌下或颊给药的药物组合物
WO1998054186A1 (en) 1997-05-26 1998-12-03 Akzo Nobel N.V. Salts of aromatic sulphonic acids
CA2304568C (en) 1997-09-30 2008-08-12 Eli Lilly And Company Olanzapine pamoate formulations
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
BRPI0516000A (pt) 2004-10-15 2008-05-06 Pfizer uso de um composto ou de um sal, solvato, hidrato ou isÈmero óptico farmaceuticamente aceitável do mesmo, método para tratar distúrbio bipolar em um mamìfero em necessidade do mesmo, e, kit para uso no tratamento de distúrbios bipolares
PL1710245T3 (pl) * 2005-04-07 2008-01-31 Merck Sharp & Dohme Postać krystaliczna maleinianu asenapiny
CA2603181A1 (en) * 2005-04-07 2006-10-12 N.V. Organon Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
TW200817414A (en) 2006-07-05 2008-04-16 Organon Nv Process for the preparation of asenapine and intermediate products used in said process
JP2011508751A (ja) 2008-01-04 2011-03-17 ナームローゼ・フエンノートチヤツプ・オルガノン アセナピンの調製方法および前記方法において使用される中間生成物

Also Published As

Publication number Publication date
JP2012530759A (ja) 2012-12-06
WO2010149727A3 (en) 2011-04-21
US8658687B2 (en) 2014-02-25
US20120237561A1 (en) 2012-09-20
CA2766291C (en) 2016-06-21
KR20120030561A (ko) 2012-03-28
JP5801295B2 (ja) 2015-10-28
KR101435296B1 (ko) 2014-08-27
CN102596172A (zh) 2012-07-18
MX2012000061A (es) 2012-06-01
TW201113018A (en) 2011-04-16
CA2766291A1 (en) 2010-12-29
AU2010264670A1 (en) 2012-01-19
US20140154322A1 (en) 2014-06-05
RU2012102247A (ru) 2013-07-27
WO2010149727A2 (en) 2010-12-29
EP2453870A2 (en) 2012-05-23
AR077225A1 (es) 2011-08-10

Similar Documents

Publication Publication Date Title
NL301291I2 (nl) sparsentan of een farmaceutisch aanvaardbaar zout daarvan
NL301248I2 (nl) atogepant of een farmaceutisch aanvaardbaar zout daarvan
NL301157I2 (nl) odevixibat of een farmaceutisch aanvaardbaar zout daarvan
NL301187I2 (nl) Rimegepant of een farmaceutisch aanvaardbaar zout daarvan
NL301035I2 (nl) upadacitinib of een farmaceutisch aanvaardbaar zout daarvan
BRPI0906467A2 (pt) forma de dose farmacêutica
NL300901I2 (nl) pibrentasvir of een farmaceutisch aanvaardbaar zout daarvan
SMT201500209B (it) Forme di dosaggio farmaceutiche a rilascio controllato
IL245328A0 (en) Pharmaceutical composition
IL229409B (en) Intranasal pharmaceutical dosage forms comprising naloxone
ZA201304709B (en) A pharmaceutical dosage form
BR112015003376A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente
BR112012011902A2 (pt) cápsula farmacêutica
IL219276A0 (en) Gastroretentive dosage forms of poorly soluble drugs
BRPI1012246A2 (pt) composição farmacêutica contendo um fármaco e sirna
DK2652652T3 (da) Medikmentadministration
EP2568979A4 (en) RATIOMETRIC COMBINATORY MEDICINE ADMINISTRATION
SI2582366T1 (sl) Farmacevtska kombinacija za zdravljenje bolečine
BR112014003802A2 (pt) composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
IL231622B (en) Pharmaceutical composition for treatment of cachexia
BRPI1005433A2 (pt) preparações farmacêuticas transdérmicas
BRPI0922653A2 (pt) preparação farmacêutica
DK2437736T3 (da) Lægemiddelindgivelsessystemer
PL2665471T3 (pl) Doustne farmaceutyczne postacie dawkowane o kontrolowanym uwalnianiu zawierające mgbg
BR112012031102A2 (pt) forma de dosagem oral sólida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]